Erasca (ERAS)
(Real Time Quote from BATS)
$2.55 USD
+0.01 (0.39%)
Updated Aug 7, 2024 09:42 AM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Price, Consensus and EPS Surprise
ERAS 2.55 +0.01(0.39%)
Will ERAS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ERAS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ERAS
Should You Buy Erasca, Inc. (ERAS) After Golden Cross?
Soft Instrument Orders Likely to Hurt PacBio's (PACB) Q1 Earnings
ERAS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's How Cresco Labs (CRLBF) is Placed Before Q1 Earnings
Should SNDL (SNDL) be in Your Portfolio Ahead of Q1 Earnings?
Should You Buy Hims & Hers Health (HIMS) Ahead of Q1 Earnings?
Other News for ERAS
Erasca Initiates SEACRAFT-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib in Patients with NRAS-Mutant Melanoma
Erasca initiates SEACRAFT-2 Phase 3 trial of naporafenib plus trametinib
Erasca to Present at Upcoming Investor Conferences in June
e.l.f. Beauty Posts Upbeat Earnings, Joins Nvidia, LiveRamp Holdings, Borr Drilling And Other Big Stocks Moving Higher On Thursday
Jaguar Health, Altamira Therapeutics, Erasca among healthcare movers